[News] American Association for Cancer Research Annual Meeting 2017

Results from an open-label, phase 2, basket trial assessing the clinical activity of neratinib in 141 patients with either HER2-mutant or HER3-mutant tumours were presented by David Hyman (Memorial Sloan Kettering Cancer Center, New York, NY, USA). Patients with HER2-mutant lung cancer (n=26), breast cancer (n=25), bladder or urinary tract cancer (n=16), colorectal cancer (n=12), biliary tract cancer (n=9), endometrial cancer (n=7), cervical cancer (n=5), gastro-oesophageal cancer (n=5), and ovarian cancer (n=4), as well as patients with solid tumours not otherwise specified (n=32; of which 15 were HER2-mutant-postive and 17 were HER3-mutant-postive), were enrolled in this study.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: News Source Type: research